"Adding Dr. Reed to our management team continues to extend our top-class scientific capabilities. Mike’s clinical pharmacology and drug development expertise combined with his significant physiologic modeling background will further enhance the relevance of our offerings to our bio-pharmaceutical clients worldwide", said Dr. Ron Beaver, PhD, Rosa’s Cofounder, Chairman, and CEO.
"I’m excited to be joining the team at Rosa," Mike added. "The application of mathematical modeling to bio-pharmaceutical development is the way forward in a field fraught with challenges. Having worked at the bench and personally faced the critical challenges of time, money, and complexity, I feel that Rosa’s approach offers a unique strategic advantage.."
About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC
